MetaCap

Opus Genetics (IRD) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Opus Genetics (IRD) has outperformed Ovid Therapeutics (OVID) over the past year, gaining 108.9% versus a gain of 57.1%. Over five years, IRD leads with a -8.3% price change compared with -32.5% for OVID. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $385.7 million), about 1.1 times the size.

Ovid Therapeutics converts more of its revenue into profit, with a net margin of -240.1% versus -349.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRD+108.90%OVID+57.14%
+229%+107%-15%
Nov 21, 20251 yearNov 20, 2026
IRD+9.62%OVID-36.05%
+78%-11%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRD versus OVID key metrics
MetricIRDOVID
Share price$3.99$2.20
Market cap$385.65M$415.21M
1-day change-2.21%-5.98%
YTD return+98.51%+34.97%
1-year return+108.90%+57.14%
5-year return-8.28%-32.52%
EPS (TTM)$-1.48$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.20M$7.25M
Revenue growth (YoY)+29.15%+1181.27%
Net income (latest FY)$-49.59M$-17.41M
Operating margin-271.90%-585.20%
Net margin-349.33%-240.13%
52-week high$7.07$3.11
52-week low$1.88$1.26
Distance from 52-week high-43.56%-29.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+249.37%+179.55%
Average volume2.56M1.98M
Shares outstanding96.65M188.73M
Employees2723
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRD has outperformed OVID by 51.8 percentage points over the past year.
  • Ovid Therapeutics is more profitable, keeping -240.1 cents of every revenue dollar as net income versus -349.3 cents for Opus Genetics.
  • Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +29.15%).

About Opus Genetics

IRD stock →

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

IRD vs OVID FAQ

Which is bigger, Opus Genetics or Ovid Therapeutics?

Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $385.65M for Opus Genetics (IRD).

Which stock has performed better over the past year, IRD or OVID?

IRD returned +108.90% over the past 12 months, compared with +57.14% for OVID (price return, excluding dividends). Past performance does not predict future results.

Are Opus Genetics and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons